Sugi Predict

Sugi Predict / Compounds / SCHEMBL29409593

SCHEMBL29409593

SCHEMBL29409593

CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(=O)O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 16/20 0.60
▸ GHSR Q92847 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30504389 0.90 KISS1R (0.64) KISS1RGHSR
SCHEMBL31375294 0.89 ERBB2 (0.55) GHSR
SCHEMBL30128808 0.89 GLP1R (0.65) KISS1R
SCHEMBL31243562 0.88 GLP1R (0.58) KISS1R
SCHEMBL31573961 0.88 ERAP2 (0.56) KISS1RGHSR
SCHEMBL31606482 0.88 GHSR (0.58) KISS1RGHSR
SCHEMBL30799526 0.87 ERAP2 (0.60) GHSR
SCHEMBL29856017 0.87 ERBB2 (0.57) KISS1R
SCHEMBL30376709 0.87 GLP1R (0.57) KISS1RGHSR
SCHEMBL31182787 0.87 GLP1R (0.65) KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263480-A1 Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant CEDARS-SINAI MEDICAL CENTER (US) 2025-08-21 — — US disclosed
CN-112969711-B Desensitization and improvement of kidney transplantation in HLA sensitized patients using cladagumab 西达赛奈医疗中心 2024-12-17 — — CN disclosed
CN-113194996-B Clazazumab for the treatment of chronic antibody-mediated organ transplant rejection 西达赛奈医疗中心 2024-06-28 — — CN disclosed
US-20220073605-A1 CLAZAKIZUMAB IN THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT CEDARS-SINAI MEDICAL CENTER (US) 2022-03-10 — — US disclosed
Send feedback